Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CBIO Crescent Biopharma Inc

交易中 09-15 14:38:19 EDT

19.00

-0.68

-3.46%

最高20.31	最低18.40	成交量18.08万
今开19.60	昨收19.68	日振幅9.68%
总市值7.06亿	流通市值3.03亿	总股本3,714万
成交额342.01万	换手率1.13%	流通股本1,595万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CBIO","market":"US","secType":"STK","nameCN":"Crescent Biopharma Inc","latestPrice":19,"timestamp":1789497497003,"preClose":19.68,"halted":0,"volume":180831,"delay":0,"changeRate":-0.03455284552845527,"floatShares":15953500,"shares":37143940,"eps":-7.4105,"marketStatus":"交易中","change":-0.68,"latestTime":"09-15 14:38:19 EDT","open":19.6,"high":20.305,"low":18.4,"amount":3420052.543887,"amplitude":0.096799,"askPrice":19.09,"askSize":339,"bidPrice":18.98,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-7.4105,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":19.68,"postHourTrading":{"tag":"盘后","latestPrice":19.68,"preClose":19.68,"latestTime":"19:30 EDT","volume":5152,"amount":101391.36,"timestamp":1789428600990,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.674456,"impliedVol":0.5531,"impliedVolPercentile":0.4103},"requestUrl":"/m/hq/s/CBIO/wiki","defaultTab":"wiki","newsList":[{"id":"1195614552","title":"Crescent Biopharma完成公开发行，包销商全额行使超额配售权","url":"https://stock-news.laohu8.com/highlight/detail?id=1195614552","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195614552?lang=zh_cn&edition=full","pubTime":"2026-07-17 04:04","pubTimestamp":1784232285,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc是一家致力于为癌症患者快速推进下一代疗法的临床阶段生物技术公司。该公司今日宣布，已完成此前公布的承销公开发行。本次发行共售出9,387,896股普通股，其中包括因包销商全额行使购买额外股份的选择权而售出的1,293,103股普通股。本次公开发行中出售的所有普通股和预融资权证均由Crescent发行。本次发行仅通过招股说明书补充文件及随附招股说明书进行。Crescent Biopharma的愿景是打造一家世界领先的肿瘤学公司，为癌症患者带来下一代疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167120504","title":"Crescent Biopharma Inc：预融资权证以每份14.499美元的公开发行价出售","url":"https://stock-news.laohu8.com/highlight/detail?id=1167120504","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167120504?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:49","pubTimestamp":1784080150,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc 的预融资权证正面向公众发售，定价为每份14.499美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193794721","title":"新闻稿：Crescent Biopharma宣布普通股及预融资权证公开发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1193794721","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193794721?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:47","pubTimestamp":1784080076,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年7月14日——致力于为癌症患者快速推进下一代疗法的临床阶段生物技术公司 Crescent Biopharma Inc今日宣布，其承销公开发行的定价已确定。此次发行包括8,094,793股普通股，以及向特定投资者发行的、可购买最多525,897股普通股的预融资权证，以替代普通股。在扣除承销折扣、佣金及公司需支付的其他发行费用前，Crescent 预计将从此次发行中获得总额约1.25亿美元的总收益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145391750","title":"Crescent Biopharma Inc. 以每股14.50美元定价其承销公开发行8,094,793股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1145391750","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145391750?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:47","pubTimestamp":1784080072,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc. 已为其8,094,793股普通股的承销公开发行定价，价格为每股14.50美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168449350","title":"Crescent Biopharma 将在2026年美国临床肿瘤学会年会上公布CR-001的Ascend研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1168449350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168449350?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:30","pubTimestamp":1779399031,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc 宣布，将在即将到来的2026年美国临床肿瘤学会（ASCO）年会上，就其PD-1 x VEGF双特异性抗体CR-001的Ascend研究，进行“试验进展”报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379512739","title":"凯赛生物：截至10月31日已回购54.9236万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2379512739","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2379512739?lang=zh_cn&edition=full","pubTime":"2023-10-31 18:12","pubTimestamp":1698747120,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月31日晚间，凯赛生物发布公告称，截至2023年10月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份54.9236万股，占公司总股本58337.8039万股的比例为0.0941%。回购成交的最高价为57.37元/股，最低价为52.90元/股，支付的资金总额人民币3057.0741万元（不含印花税、交易佣金等交易费用）。（编辑 何帆）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103118311783989b56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103118311783989b56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","688065","BK0208","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379198955","title":"凯赛生物：累计回购约55万股 占比0.0941%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379198955","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2379198955?lang=zh_cn&edition=full","pubTime":"2023-10-31 17:37","pubTimestamp":1698745056,"startTime":"0","endTime":"0","summary":"凯赛生物（SH 688065，收盘价：53.11元）10月31日晚间发布公告称，截至2023年10月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份约55万股，占公司总股本约5.83亿股的比例为0.0941%。2022年1至12月份，凯赛生物的营业收入构成为：合成生物材料行业占比95.55%。凯赛生物的董事长、总裁均是XIUCAI LIU(刘修才)，男，66岁，学历背景为博士。截至发稿，凯赛生物市值为310亿元。文章来源：每日经济新闻原标题：凯赛生物：累计回购约55万股，占比0.0941%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103117393083d61d06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103117393083d61d06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0208","GYRE","688065","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379589096","title":"Catalyst Biosciences Inc盘中异动 大幅上涨7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379589096","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2379589096?lang=zh_cn&edition=full","pubTime":"2023-10-30 21:30","pubTimestamp":1698672625,"startTime":"0","endTime":"0","summary":"北京时间2023年10月30日21时30分，Catalyst Biosciences Inc股票出现波动，股价急速拉升7.88%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.00%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时30分，《凯赛生物2023年前三季度净利3.14亿 同比减少35.44%》资讯为影响Catalyst Biosciences Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310302130258475f4fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310302130258475f4fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379304977","title":"凯赛生物2023年前三季度净利3.14亿 同比减少35.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379304977","media":"挖贝网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2379304977?lang=zh_cn&edition=full","pubTime":"2023-10-30 19:01","pubTimestamp":1698663690,"startTime":"0","endTime":"0","summary":"挖贝网2023年10月30日，凯赛生物 近日发布2023年前三季度报,报告期内，公司实现营业收入1,565,490,018.66元,同比减少14.81%；归属于上市公司股东的净利润313,885,180.71元，同比减少35.44%。报告期内研发费用126,413,295.65元，上年同期134,754,753.10元，同比减少6.19%。挖贝网资料显示，凯赛生物的主要业务为新型生物基材料的研发、生产及销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019034483d2d8f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019034483d2d8f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","688065","BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379307906","title":"凯赛生物：2023年前三季度净利润约3.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2379307906","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2379307906?lang=zh_cn&edition=full","pubTime":"2023-10-30 18:57","pubTimestamp":1698663430,"startTime":"0","endTime":"0","summary":"凯赛生物（SH 688065，收盘价：53.78元）10月30日晚间发布三季度业绩公告称，2023年前三季度营收约15.65亿元，同比减少14.81%；归属于上市公司股东的净利润约3.14亿元，同比减少35.44%。2022年1至12月份，凯赛生物的营业收入构成为：合成生物材料行业占比95.55%。凯赛生物的董事长、总裁均是XIUCAI LIU(刘修才)，男，66岁，学历背景为博士。截至发稿，凯赛生物市值为314亿元。文章来源：每日经济新闻原标题：凯赛生物：2023年前三季度净利润约3.14亿元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019100783d2dce7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019100783d2dce7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","CBIO","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2378870508","title":"Catalyst Biosciences Inc盘中异动 早盘急速拉升6.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2378870508","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2378870508?lang=zh_cn&edition=full","pubTime":"2023-10-27 21:43","pubTimestamp":1698414201,"startTime":"0","endTime":"0","summary":"北京时间2023年10月27日21时43分，Catalyst Biosciences Inc股票出现异动，股价大幅拉升6.66%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.74%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时43分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102721432383978a74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102721432383978a74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2378852295","title":"Catalyst Biosciences Inc盘中异动 大幅拉升7.55%报0.570美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2378852295","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2378852295?lang=zh_cn&edition=full","pubTime":"2023-10-26 21:35","pubTimestamp":1698327329,"startTime":"0","endTime":"0","summary":"北京时间2023年10月26日21时35分，Catalyst Biosciences Inc股票出现波动，股价快速上涨7.55%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.41%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时35分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。凯赛生物2023半年报A股排名1653，较上季度排名提高，较去年同期排名大幅下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102621353082ff2eda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102621353082ff2eda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2378041090","title":"Catalyst Biosciences Inc盘中异动 早盘大幅拉升6.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2378041090","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2378041090?lang=zh_cn&edition=full","pubTime":"2023-10-25 21:46","pubTimestamp":1698241612,"startTime":"0","endTime":"0","summary":"北京时间2023年10月25日21时46分，Catalyst Biosciences Inc股票出现异动，股价快速上涨6.68%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.99%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时46分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。凯赛生物2023半年报A股排名1653，较上季度排名提高，较去年同期排名大幅下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310252146538396bdb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310252146538396bdb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2378029061","title":"年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低（2023半年报）","url":"https://stock-news.laohu8.com/highlight/detail?id=2378029061","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2378029061?lang=zh_cn&edition=full","pubTime":"2023-10-25 10:58","pubTimestamp":1698202722,"startTime":"0","endTime":"0","summary":"凯赛生物2023半年报行业排名107，较上季度排名提高，较去年同期排名下滑。四核心财务特征2023半年报凯赛生物净利润2.64亿元，与2022半年报相比，净利润快速下滑。2023半年报凯赛生物经营资产报酬率0.68%。凯赛生物2023半年报经营活动现金净流入3.24亿元，较2023半年报减少0.37亿元，2021年报到本期经营活动累计产生净流入17.22亿元。2023半年报凯赛生物经营活动与投资活动资金缺口5.45亿元较2022半年报减少12.62亿元，缺口迅速缩小。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310251110268221ab37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310251110268221ab37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","688065","GYRE","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2377508285","title":"Catalyst Biosciences Inc股价重挫10.84% 市值跌74.44万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2377508285","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2377508285?lang=zh_cn&edition=full","pubTime":"2023-10-24 21:35","pubTimestamp":1698154556,"startTime":"0","endTime":"0","summary":"北京时间2023年10月24日21时35分，Catalyst Biosciences Inc股票出现异动，股价急速下跌10.84%。截至发稿，该股报0.416美元/股，成交量6.7714万股，换手率0.18%，振幅9.33%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.61%。其相关个股中，联拓生物、Immunitybio Inc、Maia Biotechnology Inc涨幅较大，Transcode Therapeutics Inc、Maia Biotechnology Inc、联拓生物较为活跃，换手率分别为55.27%、18.59%、12.25%，振幅较大的相关个股有Immunitybio Inc、Eiger Biopharmaceuticals Inc、联拓生物，振幅分别为17.53%、15.90%、15.76%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102421355683965f51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102421355683965f51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2377716410","title":"Catalyst Biosciences Inc盘中异动 快速跳水6.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2377716410","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2377716410?lang=zh_cn&edition=full","pubTime":"2023-10-23 21:32","pubTimestamp":1698067945,"startTime":"0","endTime":"0","summary":"北京时间2023年10月23日21时32分，Catalyst Biosciences Inc股票出现波动，股价快速下跌6.94%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.19%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时32分，《康蒂尼药业与CATALYST BIOSCIENCES,INC.合并赴美IPO获中国证监会备案 拟在纳斯达克上市》资讯为影响Catalyst Biosciences Inc的重要信息。同时，公司完成境外发行上市后15个工作日内，应通过中国证监会备案管理信息系统报告发行上市情况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231023213227821ca7e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231023213227821ca7e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2376249839","title":"Catalyst Biosciences Inc股价上涨17.03% 市值涨303.51万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2376249839","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2376249839?lang=zh_cn&edition=full","pubTime":"2023-10-20 21:31","pubTimestamp":1697808689,"startTime":"0","endTime":"0","summary":"北京时间2023年10月20日21时31分，Catalyst Biosciences Inc股票出现波动，股价急速拉升17.03%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.01%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时31分，《康蒂尼药业与CATALYST BIOSCIENCES,INC.合并赴美IPO获中国证监会备案 拟在纳斯达克上市》资讯为影响Catalyst Biosciences Inc的重要信息。同时，公司完成境外发行上市后15个工作日内，应通过中国证监会备案管理信息系统报告发行上市情况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102021313082152b37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102021313082152b37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2376192245","title":"康蒂尼药业与CATALYST BIOSCIENCES,INC.合并赴美IPO获中国证监会备案 拟在纳斯达克上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2376192245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2376192245?lang=zh_cn&edition=full","pubTime":"2023-10-20 20:49","pubTimestamp":1697806199,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月20日，证监会国际合作部发布关于北京康蒂尼药业股份有限公司境外发行上市备案通知书，康蒂尼药业此次通过与CATALYST BIOSCIENCES,INC.合并实现在美国纳斯达克证券交易所上市，CATALYST BIOSCIENCES,INC.同步发行不超过1110776224股普通股。同时，公司完成境外发行上市后15个工作日内，应通过中国证监会备案管理信息系统报告发行上市情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1009350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03086","BK4139","NQmain",".IXIC","NDX","QLD","SQQQ","BK4007","CBIO","ARTL","QQQ","QID","PSQ","TQQQ","MNQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2375160051","title":"未来产业 赢领明天丨凯赛生物：助力“碳中和”，引领可持续未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2375160051","media":"人民网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2375160051?lang=zh_cn&edition=full","pubTime":"2023-10-16 13:52","pubTimestamp":1697435540,"startTime":"0","endTime":"0","summary":"未来，凯赛生物还将进一步与客户、行业伙伴等各方深化合作，积极开拓产品下游潜在应用，共拓低碳产品，共塑可持续未来。2022年，凯赛生物持续推进连续纤维增强热塑性生物基聚酰胺复合材料的应用研发。对于未来，刘修才表示，凯赛生物将持续推动生物基产品及技术的迭代和创新，以己之力为中国乃至全球合成生物学及生物制造产业的发展提供正向驱动的力量，引领技术和行业共同可持续发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231016135931843ae22c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231016135931843ae22c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","BK0208","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2375945701","title":"Catalyst Biosciences Inc盘中异动 早盘股价大跌11.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2375945701","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2375945701?lang=zh_cn&edition=full","pubTime":"2023-10-13 21:31","pubTimestamp":1697203887,"startTime":"0","endTime":"0","summary":"北京时间2023年10月13日21时31分，Catalyst Biosciences Inc股票出现波动，股价急速下跌11.71%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.74%。其相关个股中，Bio-Path Holdings Inc、Frequency Therapeutics Inc、Outlook Therapeutics Inc涨幅较大，Bio-Path Holdings Inc、Tempest Therapeutics Inc、Tracon Pharmaceuticals Inc较为活跃，换手率分别为258.17%、44.41%、33.09%，振幅较大的相关个股有Bio-Path Holdings Inc、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Bellerophon Therapeutics Inc，振幅分别为22.35%、18.97%、16.07%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023101321312781ff6850&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023101321312781ff6850&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crescentbiopharma.com","stockEarnings":[{"period":"1week","weight":-0.0575},{"period":"1month","weight":0.1482},{"period":"3month","weight":0.0964},{"period":"6month","weight":0.9014},{"period":"1year","weight":0.5757},{"period":"ytd","weight":0.6594}],"compareEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.0199},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.1504},{"period":"1year","weight":0.1574},{"period":"ytd","weight":0.1158}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Crescent Biopharma, Inc.于2003年在特拉华州注册成立，该公司的注册地于2025年6月16日从特拉华州变更为开曼群岛。该公司是一家专注于为癌症患者提供变革性疗法的临床阶段生物技术公司。Crescent Biopharma旨在通过两大战略成为领先的肿瘤生物技术公司：首先，开发CR-001，这是一种PD-1 x VEGF双特异性抗体，旨在同时靶向PD-1免疫检查点和血管内皮生长因子(VEGF)，有望取代帕博利珠单抗成为基础治疗药物；其次，构建强大的抗体药物偶联物(ADC)产品组合。该公司计划将CR-001与ADC疗法联合使用，形成协同增效的组合疗法，以期改善多种癌症的治疗效果。CR-001的全球1/2期试验（即ASCEND试验）于2026年2月启动，预计CR-002和CR-003的进一步临床试验也将于同年开始。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.001565},{"month":2,"riseRate":0.615385,"avgChangeRate":0.005722},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.009855},{"month":4,"riseRate":0.461538,"avgChangeRate":-0.042062},{"month":5,"riseRate":0.461538,"avgChangeRate":0.07932},{"month":6,"riseRate":0.307692,"avgChangeRate":-0.030953},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.068774},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.03805},{"month":9,"riseRate":0.230769,"avgChangeRate":-0.039516},{"month":10,"riseRate":0.5,"avgChangeRate":0.107936},{"month":11,"riseRate":0.75,"avgChangeRate":0.290074},{"month":12,"riseRate":0.25,"avgChangeRate":-0.030216}],"exchange":"NASDAQ","name":"Crescent Biopharma Inc","nameEN":"Crescent Biopharma Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Crescent Biopharma Inc(CBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Crescent Biopharma Inc,CBIO,Crescent Biopharma Inc股票,Crescent Biopharma Inc股票老虎,Crescent Biopharma Inc股票老虎国际,Crescent Biopharma Inc行情,Crescent Biopharma Inc股票行情,Crescent Biopharma Inc股价,Crescent Biopharma Inc股市,Crescent Biopharma Inc股票价格,Crescent Biopharma Inc股票交易,Crescent Biopharma Inc股票购买,Crescent Biopharma Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Crescent Biopharma Inc(CBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}